Delayed
Australian S.E.
09:45:46 29/04/2024 am IST
|
5-day change
|
1st Jan Change
|
1.045
AUD
|
+12.37%
|
|
+32.08%
|
+238.71%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
730.3
|
1,886
|
1,282
|
396.4
|
923.5
|
1,061
|
-
|
-
|
Enterprise Value (EV)
1 |
776.2
|
1,845
|
1,239
|
396.4
|
981.2
|
1,116
|
1,155
|
1,129
|
P/E ratio
|
-2.73
x
|
-7.96
x
|
-4.42
x
|
-1.49
x
|
-3.33
x
|
-8.77
x
|
-8.64
x
|
-13.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
29.4
x
|
42.3
x
|
125
x
|
26.7
x
|
80
x
|
92.2
x
|
42.7
x
|
4.49
x
|
EV / Revenue
|
31.2
x
|
41.4
x
|
121
x
|
26.7
x
|
84.9
x
|
96.9
x
|
46.5
x
|
4.77
x
|
EV / EBITDA
|
-6.7
x
|
-18.9
x
|
-10.7
x
|
-3.9
x
|
-11
x
|
-18.2
x
|
-14.5
x
|
-21.2
x
|
EV / FCF
|
-9
x
|
-22.8
x
|
-8.36
x
|
-4.14
x
|
-10
x
|
-14.3
x
|
-12.2
x
|
42.1
x
|
FCF Yield
|
-11.1%
|
-4.39%
|
-12%
|
-24.2%
|
-9.97%
|
-7%
|
-8.22%
|
2.38%
|
Price to Book
|
-
|
3.7
x
|
-
|
-
|
0.6
x
|
1.22
x
|
1.52
x
|
2.03
x
|
Nbr of stocks (in thousands)
|
4,95,126
|
5,80,450
|
6,47,399
|
6,49,912
|
8,13,662
|
11,41,241
|
-
|
-
|
Reference price
2 |
1.475
|
3.250
|
1.980
|
0.6100
|
1.135
|
0.9300
|
0.9300
|
0.9300
|
Announcement Date
|
29/08/19
|
26/08/20
|
30/08/21
|
30/08/22
|
30/08/23
|
-
|
-
|
-
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24.85
|
44.57
|
10.22
|
14.84
|
11.55
|
11.52
|
24.85
|
236.4
|
EBITDA
1 |
-115.8
|
-97.4
|
-115.9
|
-101.6
|
-89.11
|
-61.46
|
-79.39
|
-53.31
|
EBIT
1 |
-119
|
-102.5
|
-121.9
|
-107.9
|
-95.44
|
-76.46
|
-89.55
|
73.92
|
Operating Margin
|
-478.87%
|
-229.89%
|
-1,192.54%
|
-727.41%
|
-826.28%
|
-663.85%
|
-360.36%
|
31.27%
|
Earnings before Tax (EBT)
1 |
-146.7
|
-120.8
|
-136.5
|
-133.1
|
-126.4
|
-103.4
|
-121.6
|
53.95
|
Net income
1 |
-133.4
|
-107.8
|
-135.4
|
-132.7
|
-126.1
|
-103.3
|
-121.2
|
31.14
|
Net margin
|
-537.01%
|
-241.93%
|
-1,325.25%
|
-894.33%
|
-1,091.71%
|
-897.02%
|
-487.68%
|
13.17%
|
EPS
2 |
-0.5396
|
-0.4081
|
-0.4476
|
-0.4091
|
-0.3412
|
-0.1061
|
-0.1077
|
-0.0690
|
Free Cash Flow
1 |
-86.28
|
-80.93
|
-148.3
|
-95.8
|
-97.83
|
-78.19
|
-94.96
|
26.81
|
FCF margin
|
-347.26%
|
-181.56%
|
-1,450.88%
|
-645.57%
|
-846.99%
|
-678.9%
|
-382.15%
|
11.34%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
86.11%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/08/19
|
26/08/20
|
30/08/21
|
30/08/22
|
30/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
2025 S1
|
2025 Q3
|
2025 S2
|
---|
Net sales
1 |
29.26
|
18
|
4.596
|
5.359
|
4.978
|
3.342
|
-
|
2.806
|
3.234
|
6.156
|
2.267
|
3.173
|
5.407
|
2.98
|
3.294
|
5.951
|
5.219
|
-
|
6.612
|
3.998
|
-
|
5.843
|
5.612
|
-
|
6.228
|
EBITDA
|
-39.9
|
-61.15
|
-58.17
|
-54.44
|
-
|
-
|
-52.58
|
-
|
-
|
-47.1
|
-
|
-
|
-42.56
|
-
|
-
|
-45.04
|
-30.62
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-42.52
|
-63.85
|
-60.83
|
-57.55
|
-26.38
|
-28.95
|
-55.66
|
-24.32
|
-24.94
|
-50.28
|
-18.77
|
-27.32
|
-45.82
|
-21
|
-26.96
|
-49.36
|
-34.39
|
-
|
-
|
-42.29
|
-
|
-
|
-44.13
|
-
|
-45.9
|
Operating Margin
|
-145.31%
|
-354.81%
|
-1,323.35%
|
-1,073.91%
|
-529.97%
|
-866.35%
|
-
|
-867.03%
|
-771.34%
|
-816.76%
|
-827.81%
|
-860.78%
|
-847.39%
|
-704.59%
|
-818.47%
|
-829.47%
|
-658.86%
|
-
|
-
|
-1,057.7%
|
-
|
-
|
-786.32%
|
-
|
-737.02%
|
Earnings before Tax (EBT)
|
-
|
-73.37
|
-65.97
|
-66.8
|
-31.45
|
-36.49
|
-
|
-29.78
|
-31.25
|
-62.26
|
-25.55
|
-36.52
|
-61.71
|
-28.66
|
-33.81
|
-63.9
|
-50.28
|
-
|
-
|
-57.66
|
-
|
-
|
-59.7
|
-
|
-64.2
|
Net income
|
-45.87
|
-66.17
|
-65.12
|
-66.57
|
-31.37
|
-36.38
|
-
|
-29.72
|
-31.17
|
-62.12
|
-25.47
|
-36.41
|
-61.52
|
-28.59
|
-33.75
|
-62.39
|
-50.13
|
-
|
-
|
-57.66
|
-
|
-
|
-59.7
|
-
|
-64.2
|
Net margin
|
-156.77%
|
-367.69%
|
-1,416.69%
|
-1,242.33%
|
-630.08%
|
-1,088.75%
|
-
|
-1,059.27%
|
-963.84%
|
-1,009.13%
|
-1,123.35%
|
-1,147.42%
|
-1,137.79%
|
-959.26%
|
-1,024.73%
|
-1,048.36%
|
-960.42%
|
-
|
-
|
-1,442.32%
|
-
|
-
|
-1,063.72%
|
-
|
-1,030.83%
|
EPS
|
-
|
-
|
-
|
-0.2119
|
-0.0967
|
-0.1122
|
-
|
-
|
-
|
-0.0959
|
-
|
-0.0987
|
-0.1719
|
-0.0778
|
-0.0859
|
-
|
-0.0588
|
-
|
-
|
-0.0620
|
-
|
-
|
-0.0620
|
-
|
-0.0620
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/20
|
26/08/20
|
26/02/21
|
30/08/21
|
23/11/21
|
24/02/22
|
24/02/22
|
01/06/22
|
30/08/22
|
30/08/22
|
22/11/22
|
27/02/23
|
27/02/23
|
25/05/23
|
30/08/23
|
30/08/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
45.9
|
-
|
-
|
-
|
57.7
|
55.1
|
93.3
|
67.3
|
Net Cash position
1 |
-
|
41.5
|
43
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.396
x
|
-
|
-
|
-
|
-0.647
x
|
-0.8957
x
|
-1.175
x
|
-1.262
x
|
Free Cash Flow
1 |
-86.3
|
-80.9
|
-148
|
-95.8
|
-97.8
|
-78.2
|
-95
|
26.8
|
ROE (net income / shareholders' equity)
|
-17.5%
|
-44.6%
|
-17.5%
|
-
|
-16.4%
|
-12.8%
|
-15.9%
|
-13.1%
|
ROA (Net income/ Total Assets)
|
-13.4%
|
-11.4%
|
-13.4%
|
-
|
-12.3%
|
-7.6%
|
-10.1%
|
-8.9%
|
Assets
1 |
998.9
|
943.7
|
1,013
|
-
|
1,025
|
1,359
|
1,200
|
-349.9
|
Book Value Per Share
2 |
-
|
0.8800
|
-
|
-
|
1.900
|
0.7700
|
0.6100
|
0.4600
|
Cash Flow per Share
|
-0.3500
|
-0.3000
|
-0.4800
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.41
|
2.9
|
2.25
|
0.23
|
0.41
|
3.58
|
4.09
|
8.67
|
Capex / Sales
|
1.67%
|
6.51%
|
22.06%
|
1.54%
|
3.52%
|
31.08%
|
16.45%
|
3.67%
|
Announcement Date
|
29/08/19
|
26/08/20
|
30/08/21
|
30/08/22
|
30/08/23
|
-
|
-
|
-
|
Last Close Price
0.93
AUD Average target price
1.1
AUD Spread / Average Target +18.28% Consensus |
1st Jan change
|
Capi.
|
---|
| +238.71% | 692M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|